Categories
Cardiovascular
Diagnostics
Endocrinology
Health Insurance
Medical Devices
Mental Health
Nutrition
Oncology
Public Health
Sexual Health
Popular Articles
Herbal Products

Progress In Osteoporosis: Free Online Journal
No time to keep abreast of the most important osteoporosis-related research? Progress in Osteoporosis, the free online journal published by the International Osteoporosis Foundation (IOF) on http://www.iofbonehealth.org/pio provides concise summaries of new research published in the preceding three to four months. The journal is edited by leading osteoporosis researcher and author, Professor Ego Seeman of the University of Melbourne, Australia.
generic viagra online
People Who Bike Or Walk To Work Are More Fit, Less Fat Than Drivers
Trying to get fit but can"t work it into your daily schedule? Incorporating even relatively short bouts of exercise into a daily commute appears to deliver significant rewards, according to a new study from the University of North Carolina at Chapel Hill.
News of the day
ARYx Therapeutics Announces Results Of Phase 2/3 Clinical Trial On Anticoagulant Agent Tecarfarin
ARYx Therapeutics, Inc. (NASDAQ:ARYX), a biopharmaceutical company, announced results from its Phase 2/3 clinical trial, EmbraceAC, comparing its novel anticoagulant agent tecarfarin (previously ATI-5923) with the leading oral anticoagulant warfarin. In this trial, tecarfarin demonstrated efficacy essentially the same as in earlier Phase 2 studies but did not achieve the primary endpoint of superiority over warfarin, as measured by time in therapeutic range (TTR). This was due to the virtually unprecedented performance of warfarin in this trial. Using the International Normalized Ratio (INR), which is the standard measure of anticoagulation to evaluate TTR, the patients in the trial who were administered tecarfarin stayed within the target therapeutic range 74.0% of the time treated as compared to those patients receiving warfarin who stayed within the target therapeutic range 73.2% of the time (p=0.506). The result for the warfarin group was unexpected based upon the extensive history of prior studies and published literature for the drug. Tecarfarin appeared to be well tolerated by the patients in this Phase 2/3 clinical trial.
Public Health

HHS Secretary Sebelius Picks Georgetown's Mann To Head Center For Medicaid And State Operations

HHS Secretary Kathleen Sebelius on Friday appointed Cindy Mann, director of Georgetown University"s Center for Children and Families, to head the Center for Medicaid and State Operations, a division of the Centers for Medicare and Medicaid Services, BNA reports. Mann is a former director of the Family and Children"s Health Programs at CMSO from 1999 to 2001. Sebelius said Mann has been "instrumental in recent efforts to expand health care coverage in our country." She added that Mann"s "knowledge of health care issues and management experience will be a great asset to CMSO and to the millions of Americans who rely on Medicaid" (BNA, 6/1). Reprinted with kind permission from http://www.nationalpartnership.org. You can view the entire Daily Women"s Health Policy Report, search the archives, or sign up for email delivery here. The Daily Women"s Health Policy Report is a free service of the National Partnership for Women & Families, published by The Advisory Board Company. © 2009 The Advisory Board Company. All rights reserved.


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):

© Copyright 2009